Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALCNASDAQ:DRRXNASDAQ:GTBPNASDAQ:KALA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$1.64-3.0%$1.73$1.43▼$5.97$22.91M1.2645,745 shs14,521 shsDRRXDURECT$0.69+5.4%$0.62$0.48▼$1.74$21.48M0.5964,857 shs24,778 shsGTBPGT Biopharma$3.05+3.7%$2.54$1.72▼$4.10$7.89M1.37246,251 shs17,991 shsKALAKALA BIO$4.04-4.7%$3.78$2.92▼$11.20$26.06M-1.9895,793 shs23,275 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica0.00%-4.65%-8.89%-21.15%-69.35%DRRXDURECT0.00%+12.52%+27.21%-18.49%-54.17%GTBPGT Biopharma0.00%+7.39%+5.54%+30.90%+4.45%KALAKALA BIO0.00%-6.05%0.00%-41.11%-25.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALCCalciMedica2.8294 of 5 stars3.55.00.00.00.63.30.0DRRXDURECT0.5926 of 5 stars0.03.00.04.40.60.00.0GTBPGT Biopharma1.5613 of 5 stars3.82.00.00.00.60.00.6KALAKALA BIO2.4384 of 5 stars3.51.00.04.40.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALCCalciMedica 3.00Buy$18.00997.56% UpsideDRRXDURECT 2.00HoldN/AN/AGTBPGT Biopharma 3.50Strong Buy$11.00260.66% UpsideKALAKALA BIO 3.00Buy$13.50234.16% UpsideCurrent Analyst Ratings BreakdownLatest GTBP, DRRX, KALA, and CALC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.005/23/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/15/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/4/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.004/1/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/27/2025DRRXDURECTHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALCCalciMedicaN/AN/AN/AN/A$1.07 per shareN/ADRRXDURECT$2.03M10.58N/AN/A$0.29 per share2.39GTBPGT BiopharmaN/AN/AN/AN/A($0.75) per shareN/AKALAKALA BIO$3.89M6.70N/AN/A$2.02 per share2.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALCCalciMedica-$13.70M-$1.56N/AN/AN/AN/A-171.81%-100.43%8/11/2025 (Estimated)DRRXDURECT-$8.32M-$0.15N/AN/AN/A-91.54%-267.36%-64.00%8/12/2025 (Estimated)GTBPGT Biopharma-$13.16M-$5.69N/AN/AN/AN/A-1,033.08%-223.20%8/13/2025 (Estimated)KALAKALA BIO-$38.51M-$8.24N/AN/AN/AN/A-369.29%-64.99%8/5/2025 (Estimated)Latest GTBP, DRRX, KALA, and CALC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GTBPGT Biopharma-$0.64-$0.76-$0.12-$0.33N/AN/A5/14/2025Q1 2025CALCCalciMedica-$0.43-$0.36+$0.07-$0.36N/AN/A3/28/2025Q4 2024KALAKALA BIO-$2.28-$1.74+$0.54-$1.74N/AN/A3/27/2025Q4 2024CALCCalciMedica-$0.48-$0.34+$0.14-$0.34N/AN/A3/26/2025Q4 2024DRRXDURECT$0.06-$0.06-$0.12$0.24$6.91 million$2.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALCCalciMedicaN/AN/AN/AN/AN/ADRRXDURECTN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALCCalciMedica0.795.665.66DRRXDURECTN/A1.231.22GTBPGT BiopharmaN/A0.730.73KALAKALA BIO3.191.991.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALCCalciMedicaN/ADRRXDURECT28.03%GTBPGT Biopharma8.15%KALAKALA BIO24.61%Insider OwnershipCompanyInsider OwnershipCALCCalciMedica41.55%DRRXDURECT3.20%GTBPGT Biopharma3.40%KALAKALA BIO8.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALCCalciMedica3013.97 million8.17 millionNo DataDRRXDURECT8031.04 million30.05 millionOptionableGTBPGT Biopharma82.59 million2.50 millionNo DataKALAKALA BIO306.45 million5.92 millionNot OptionableGTBP, DRRX, KALA, and CALC HeadlinesRecent News About These CompaniesMary Reumuth Sells 2,850 Shares of KALA BIO, Inc. (NASDAQ:KALA) StockJune 5, 2025 | insidertrades.comKALA BIO to Present at Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comKALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | finance.yahoo.comChief Minister cancels programme over unauthorised nature of venueApril 20, 2025 | thehindu.comKALA BIO: Q4 Earnings SnapshotMarch 31, 2025 | timesunion.comKALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | markets.businessinsider.comKALA BIO to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | finance.yahoo.comKala Bio announces CEO departure, appoints interim leaderFebruary 13, 2025 | msn.comKALA BIO, Inc.: KALA BIO Announces Chief Executive Officer TransitionFebruary 12, 2025 | finanznachrichten.deKala Bio appoints new interim CEO amid leadership shuffleFebruary 12, 2025 | msn.comKala announces resignation of CEO Iwicki, Bazemore appointed interim CEOFebruary 12, 2025 | markets.businessinsider.comKala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An OverreactionFebruary 12, 2025 | msn.comKALA BIO Announces Chief Executive Officer TransitionFebruary 12, 2025 | globenewswire.comKALA stock soars to 52-week high, reaching $8.81January 29, 2025 | msn.comKala Pharmaceuticals files to sell 1.67M shares of common stock for holdersJanuary 24, 2025 | markets.businessinsider.comKALA BIO, Inc. (NASDAQ:KALA) CFO Sells $13,016.78 in StockJanuary 8, 2025 | insidertrades.comBros. Advisors Lp Baker Purchases 310,559 Shares of KALA BIO, Inc. (NASDAQ:KALA) StockJanuary 1, 2025 | insidertrades.comKALA BIO, Inc. Secures $10.75 Million in Private Placement to Advance Clinical Development of KPI-012December 30, 2024 | quiverquant.comKALA BIO Announces $10,750,000 Private PlacementDecember 30, 2024 | globenewswire.comKALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?December 16, 2024 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGTBP, DRRX, KALA, and CALC Company DescriptionsCalciMedica NASDAQ:CALC$1.64 -0.05 (-2.96%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.64 0.00 (-0.30%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.DURECT NASDAQ:DRRX$0.69 +0.04 (+5.38%) As of 06/20/2025 04:00 PM EasternDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.GT Biopharma NASDAQ:GTBP$3.05 +0.11 (+3.74%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.04 -0.01 (-0.33%) As of 06/20/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.KALA BIO NASDAQ:KALA$4.04 -0.20 (-4.72%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$4.12 +0.08 (+1.98%) As of 06/20/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
